The blood pressure cut off for diagnosis of preeclampsia has historically been based on hypertension criteria defined by the American College of Cardiology (ACC) and American Heart Association (AHA). Recently, they decreased their criteria, defining stage 1 hypertension as a blood pressure greater than 130/80, raising the question as to whether the new definition should be adopted in pregnancy. We aimed to evaluate whether women meeting this new blood pressure threshold at the time of admission for labor had an increased risk for adverse neonatal outcomes. STUDY DESIGN: This is a retrospective cohort study of all women with singleton pregnancies admitted for delivery at a tertiary care center from [2004][2005][2006][2007][2008][2009][2010][2011][2012][2013][2014]. Using blood pressure on admission, women were classified into three groups: 1) normotensive if their blood pressure was <130/80, 2) stage 1 hypertension if their blood pressure was 130-139/80-89, or 3) overt hypertension if their blood pressure was >140/90. Patients with preexisting chronic hypertension were excluded. The risk of small for gestational age (SGA), 5-minute Apgar score <7, and higher level nursery admission were examined across groups. Baseline characteristics were compared using chi square and ANOVA. Neonatal outcomes were compared with the normotensive group as the reference using logistic regression to control for confounders. RESULTS: 28,993 women met inclusion criteria, 14,685 (51%) were classified as normotensive, 7,828 (27%) were classified as stage 1 hypertension, and 6,480 (22%) were classified as having overt hypertension. Women with hypertensive disorders were more likely to be older, nulliparous, African American, obese, and have pregestational diabetes. Incidence of SGA increased across the three groups (12.5%, 13.1%, 15.7%) but was only statistically significant for women with overt hypertension (aOR 1.56, 95% CI 1.02-1.31). The risk of Apgar <7 at 5 minutes and higher order nursery admission was significantly increased in the overt hypertension group only (Table) . CONCLUSION: The impact of lowering the diagnostic criteria for hypertension in pregnancy according to the new ACC/AHA criteria has unknown impact for obstetric patients. These results suggest that rates of SGA and immediate neonatal outcomes may be similar among normotensive patients and those with blood pressure elevations of 130-139/80-89. Further research is required before diagnostic criteria for hypertension are lowered in pregnancy.
431 Cost-effectiveness of telehealth blood pressure monitoring in postpartum women with hypertension Brenda Niu, Oguzhan Alagoz, Kara Hoppe University of Wisconsin, Madison, WI OBJECTIVE: Postpartum hypertension is the leading cause of postpartum readmissions in the US. The objective of this study was to evaluate the cost-effectiveness of telehealth blood pressure monitoring of postpartum women with hypertensive disorders from the hospital's perspective. STUDY DESIGN: A decision tree was developed based on results from a non-randomized controlled trial comparing telehealth to standard outpatient blood pressure monitoring. Upon postpartum discharge from the hospital, we issued remote monitoring equipment including a Bluetooth tablet, blood pressure cuff, and scale to postpartum women at a single academic center who were diagnosed with a hypertensive disorder in the antenatal or postnatal period. Patients transmitted vital signs daily to a telehealth nurse, who used an outpatient treatment algorithm to monitor patients, manage antihypertensive medications, or refer for emergent care if symptomatic. We followed patients for 6 weeks and performed costeffectiveness analysis by using data from hospital and device manufacturer supplied charges and literature-derived utilities. A cost-effectiveness threshold was set at $100,000/quality-adjusted life years. One-way sensitivity analyses were performed to evaluate the robustness of our baseline assumptions. RESULTS: 214 telehealth and 214 control participants were enrolled. Telehealth monitoring significantly reduced postpartum readmissions, from 3.7% (8/214) to 0.5% (1/214). Our study demonstrated that telehealth monitoring was not only cost-effective, but cost-saving. The telehealth cost per patient was $319 and found to be cost-effective up to $423 per patient. Similarly, telehealth monitoring remained cost-effective down to an admission cost of $11,245 compared to our average admission cost of $14,401. Telehealth monitoring also remained cost-effective down to an admission rate of 2.9% with standard monitoring. CONCLUSION: Our study demonstrates that telehealth blood pressure monitoring of postpartum women with hypertension is cost-effective, cost-saving, and reduces postpartum readmissions.
432 The association of magnesium sulfate with maternal morbidity when used for preeclampsia without severe features beyond oxytocin, MgSO 4 toxicity requiring calcium gluconate, neonatal ICU admission and perinatal death. PPH was defined by an EBL 1500 mL at delivery or the immediate postpartum period, a blood transfusion, or a hysterectomy for hemorrhage or atony. Comparisons were made based on the administration of of MgSO 4 anytime during the delivery hospitalization. Multivariable logistic regression was used to adjust for confounding. RESULTS: Of the women in the initial cohort, 2,468 (2.1%) met inclusion criteria. The groups differed by maternal race, insurance status, tobacco/drug use and gestational age at birth. The crude and adjusted odds ratios (OR) are in Table. The frequency of composite maternal morbidity was significantly higher in women who received MgSO 4 (8.6%) compared with those who did not (3.9%; aOR 2.1). Those who received MgSO 4 had 4-fold higher odds of ICU admission (aOR 4.2) and were more likely to require additional uterotonics (aOR 1.6). Neonatal outcomes were similar. Magnesium toxicity occurred in 7 women (0.5%). Results were similar after adjustment for hospital. CONCLUSION: When MgSO 4 is used in preeclampsia without severe features, it is associated with an increased risk of severe maternal morbidity.
433 Small for gestational age: Is neonatal morbidity related to preeclampsia?
Clifton O. Brock, Baha M. Sibai, PETRA Investigators
McGovern Medical School -University of Texas at Houston (UTHealth), Houston, TX OBJECTIVE: Diagnosis of small for gestational age (SGA) newborns often occurs in the setting of pre-eclampsia (PreE) due to placental insufficiency. However, it is unclear whether the poor outcomes associated with SGA are caused by co-existing PreE, or simply related to the early gestational age (GA) at which these neonates deliver. STUDY DESIGN: This is a secondary analysis of a prospective multicenter study designed to evaluate the role of placental growth factor in predicting PreE. Women were included in the parent study if they presented with concern for developing PreE. In our analysis, all women from the parent study with singleton, non-anomalous pregnancies who delivered a neonate with SGA were included. Women who developed PreE were compared to those who did not. The primary outcome was composite neonatal morbidity and mortality (Table 1) . Secondary outcomes included respiratory distress syndrome (RDS), 5-minute Apgar score < 4, arterial cord gas pH less than 7.1, and cesarean delivery. Univariate analysis was performed to compare characteristics and outcomes between the groups. To control for GA, the groups were compared after stratification (i.e. delivery before vs after 32 weeks GA). Finally, multivariate logistic regression models were fit to determine adjusted odds ratios associated with PreE and GA at delivery for each outcome. RESULTS: Of the 337 women that delivered an SGA neonate, 258 (77%) had PreE and 79 (23%) did not. The two groups had similar maternal age, BMI, rates of chronic hypertension, and pre-gestational diabetes. Women that developed PreE were more likely to be nulliparous, African American, or have pre-existing renal disease. Women that developed PreE delivered at earlier gestational ages (33 vs. 36 weeks, p < 0.01) with higher rates of composite neonatal morbidity (12% vs. 4%, p < 0.01) and Cesarean delivery (65% vs. 51%, p ¼ 0.02, Table 1 ). However, after stratification by gestational age, there were no differences in any of these outcomes (Table 2) . By multivariate analysis, PreE did not contribute to neonatal morbidity (OR ¼ 1.3, 95% CI 0.3 e 6.9). Instead, decreasing GA at delivery was strongly associated with neonatal morbidity (OR ¼ 0.6, 95% CI 0.5 e 0.7). CONCLUSION: Among SGA newborns, GA at delivery, not concomitant PreE, is associated with neonatal morbidity. Risk of RDS, low Apgars scores, and Cesarean delivery are also independent of PreE.
